Stocks that Could Benefit from a Study of THCV


THCV, or tetrahydrocannabivarin may have the potential to help with energy, focus/attention, and eve appetite, weight/BMI. In fact, in a study of 900 adults aged 21 and older in the U.S.,

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science, Inc.’s Radicle Energy rare cannabinoid program.  Tetrahydrocannabivarin, also known as THCV, or d9-THCV, is a naturally occurring compound of the Cannabis sativa plant, and is an analog of the better-known major cannabinoid, tetrahydrocannabinol.

While these two cannabinoids share a similar structure and name, they have very different physiological effects. Notably, unlike THC which is intoxicating and produces a “high” or euphoric effect, and is a scheduled compound that is federally illegal unless prescribed by a physician, THCV is non-intoxicating and is not a scheduled compound. Success could also be positive for companies such as Tilray Inc. (NASDAQ: TLRY), Canopy Growth (TSX: WEED) (NASDAQ: CGC), Jazz Pharmaceuticals (NASDAQ: JAZZ), and AbbVie Inc. (NYSE: ABBV).